Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®Business Wire • 04/17/24
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire • 03/26/24
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028Seeking Alpha • 03/20/24
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?Zacks Investment Research • 03/13/24
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common StockBusiness Wire • 03/11/24
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 GuidanceBusiness Wire • 03/07/24
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor ConferencesBusiness Wire • 02/27/24
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024Business Wire • 02/22/24
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 GuidanceBusiness Wire • 01/16/24
Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?Zacks Investment Research • 01/10/24
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate CommunicationsBusiness Wire • 01/04/24
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in EuropeBusiness Wire • 12/20/23
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®Business Wire • 11/07/23
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual MeetingBusiness Wire • 11/06/23
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual MeetingBusiness Wire • 10/25/23